Semaglutide API Peptide Raw Powder Synthesis CAS 910463-68-2
- Description
- Inquiry
Specification:
Semaglutide is a glucagon-like peptide-1 (GLP-1) analog and functions as a GLP-1 agonist. It is indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus.
Limitations of Use
- Semaglutide is not recommended as a first-line therapy for patients who have inadequate glycemic control on diet and exercise because of the uncertain relevance of rodent C-cell tumor findings to humans.
- Semaglutide has not been studied in patients with a history of pancreatitis. Consider other antidiabetic therapies in patients with a history of pancreatitis.
- Semaglutide is not a substitute for insulin. Semaglutide is not indicated for use in patients with type 1 diabetes mellitus or for the treatment of patients with diabetic ketoacidosis, as it would not be effective in these settings.
| Product Name | Semaglutide |
| Cas No. | 910463-68-2 |
| Sequence | H-His-Aib-Glu-Gly-Thr-Phe-Thr-Ser-Asp-Val-Ser-Ser-Tyr-Leu-Glu-Gly-Gln-Ala-Ala-Lys(AEEAc-AEEAc-γ-Glu-17-carboxyheptadecanoyl)-Glu-Phe-Ile-Ala-Trp-Leu-Val-Arg-Gly-Arg-Gly-OH |
| Molecular Formula | C187H291N45O59 |
| Molar Mass | 4,113.64 g·mol |
| Purity | ≥98% |
| Impurity | ≤0.5% |
| Storage Temperature | 2-8ºC |
| Packing Size | min.1G, vial or aluminum foil bag. |
Related Products
-
204656-20-2 Liraglutide Peptides API
This is peptides that used for producing injection liraglutide, with pen injectors, the diabetes can do subcutaneous tissue injection to lower down sugar blood.
Specification:
CAS No.: 204656-20-2
Molecular Formula:C172H265N43O51
Molar Mass:3751.202g/mol
Sequence: H-His-Ala-Glu-Gly-Thr-Phe-Thr-Ser-Asp-Val-Ser-Ser-Tyr-Leu-Glu-Gly-Gln-Ala-Ala-Lys(N-ε-(Nα-Palmitoyl-L-γ-glutamyl))-Glu-Phe-Ile-Ala-Trp-Leu-Val-Arg-Gly-Arg-Gly-OH. -
Polypeptide Teriparatide API CAS 52232-67-4
